scispace - formally typeset
P

Paul Ellis

Researcher at King's College London

Publications -  95
Citations -  8567

Paul Ellis is an academic researcher from King's College London. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 37, co-authored 93 publications receiving 7786 citations. Previous affiliations of Paul Ellis include King's College & St Thomas' Hospital.

Papers
More filters
Journal ArticleDOI

Breast cancer in older women: trials and tribulations.

TL;DR: This paper aims to provide a history of surgical oncology practice in the neonatal intensive care unit and some of the operations performed at yGuy’s Hospital over a 12-month period in order to establish a histopathological basis for prognosis and provide a baseline for future studies.
Journal ArticleDOI

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.

TL;DR: Although this was a small nonrandomized trial, the observation of different hematologic toxicity at the two starting concentrations but similar antitumor activity further suggests that these effects may be associated with different plasma etoposide concentrations.
Journal ArticleDOI

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

TL;DR: Analysis of 131 tissue microarray cores demonstrated that the extent of HER2-HER3 dimer formation as measured by Förster Resonance Energy Transfer determined through FLIM predicts the likelihood of metastatic relapse up to 10 years after surgery, and Interestingly there was no correlation between the level of Her2 protein expressed and Her2- HER3 heterodimer formation.
Journal Article

Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy.

TL;DR: The vaccination rate in this at-risk population is lower than the overall national uptake in those aged 65 and over, and in those patients older than 65 years and with co-morbidities.
Journal ArticleDOI

An overview of drug development for metastatic breast cancer

TL;DR: Better trial design with a focus on biomarkers should lower barriers to regulatory approval as well as increase cost effectiveness and it appears worthwhile to adopt less conventional approaches to breast cancer care.